Last checked at 31 Mar 2020 07:00
31 March 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory 3D genome architecture using its liquid biopsy platform EpiSwitch™, announces that it has today granted a total of 925,598 options over its ordinary shares of 1 pence each, to Chief Executive Officer Dr Jon Burrows, who is a Director of the Company. The options were granted under the Company's 2016 Non-Employee Share Option Plan with an exercise price of 100 pence per share.
One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.
Following this grant, Jon Burrows holds 925,598 options. The notifications below, which are made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Jon Burrows |
2 | Reason for the notification | |
a) | Position/status | Director/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Grant of share options |
c) | Price(s) and volume(s) | 925,598 ordinary shares at an exercise price of 100 pence per share
|
d) | Aggregated information - Aggregated volume - Price
| N/A
|
e) | Date of the transaction | 30 March 2020
|
f) | Place of the transaction | Outside a trading venue |
For further details please contact:
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
| +44 (0)1865 518910 |
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield John More
| +44 (0)20 7408 4090 |
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins
| +44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.